骨科患者华法林治疗个体化的药物基因组学考量 - Suppr

Suppr

超能文献

Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.

作者信息

Rhee Sonja, Walsh Kelly, Lewis Daniel, Davis George, Smith Kelly M

机构信息

University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.

出版信息

Orthopedics. 2010 Nov;33(11):828. doi: 10.3928/01477447-20100924-19.

DOI:10.3928/01477447-20100924-19

PMID:21053849

Abstract

摘要

相似文献

Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.

Orthopedics. 2010 Nov;33(11):828. doi: 10.3928/01477447-20100924-19.

Refining the use of warfarin through genetic testing.

Int Angiol. 2008 Aug;27(4):271-3.

Dynamic pharmacogenetic models in anticoagulation therapy.

Clin Lab Med. 2008 Dec;28(4):539-52. doi: 10.1016/j.cll.2008.10.002.

Using genetic testing to guide warfarin therapy.

Nursing. 2012 May;42(5):63-5. doi: 10.1097/01.NURSE.0000413324.63683.ed.

Warfarin pharmacogenetics: ready for clinical utility?

Clin Lab Sci. 2009 Summer;22(3):151-5.

Pharmacogenetic-based dosing of warfarin.

Med Lett Drugs Ther. 2008 May 19;50(1286):39-40.

The long and winding road to warfarin pharmacogenetic testing.

J Am Coll Cardiol. 2010 Jun 22;55(25):2813-5. doi: 10.1016/j.jacc.2010.04.006.

Pharmacogenomic testing for warfarin dosing: we are ready now.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1483-5. doi: 10.1586/erc.09.117.

Warfarin and pharmacogenomic testing: what would Pascal do?

Pharmacotherapy. 2009 Mar;29(3):245-7. doi: 10.1592/phco.29.3.245.

Pathology consultation on warfarin pharmacogenetic testing.

Am J Clin Pathol. 2011 Jan;135(1):13-9. doi: 10.1309/AJCPAO82OTNPUBLW.

引用本文的文献

The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty.

J Orthop. 2015 Nov 28;12(Suppl 2):S145-51. doi: 10.1016/j.jor.2015.10.023. eCollection 2015 Dec.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pharmacogenomic considerations for customizing warfarin therapy in the orthopedic patient.

Orthopedics. 2010 Nov;33(11):828. doi: 10.3928/01477447-20100924-19.

Refining the use of warfarin through genetic testing.

Int Angiol. 2008 Aug;27(4):271-3.

Dynamic pharmacogenetic models in anticoagulation therapy.

Clin Lab Med. 2008 Dec;28(4):539-52. doi: 10.1016/j.cll.2008.10.002.

Using genetic testing to guide warfarin therapy.

Nursing. 2012 May;42(5):63-5. doi: 10.1097/01.NURSE.0000413324.63683.ed.

Warfarin pharmacogenetics: ready for clinical utility?

Clin Lab Sci. 2009 Summer;22(3):151-5.

Pharmacogenetic-based dosing of warfarin.

Med Lett Drugs Ther. 2008 May 19;50(1286):39-40.

The long and winding road to warfarin pharmacogenetic testing.

J Am Coll Cardiol. 2010 Jun 22;55(25):2813-5. doi: 10.1016/j.jacc.2010.04.006.

Pharmacogenomic testing for warfarin dosing: we are ready now.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1483-5. doi: 10.1586/erc.09.117.

Warfarin and pharmacogenomic testing: what would Pascal do?

Pharmacotherapy. 2009 Mar;29(3):245-7. doi: 10.1592/phco.29.3.245.

Pathology consultation on warfarin pharmacogenetic testing.

Am J Clin Pathol. 2011 Jan;135(1):13-9. doi: 10.1309/AJCPAO82OTNPUBLW.

引用本文的文献

The influence of VKORC1 and CYP2C9 mutations on warfarin response after total hip and knee arthroplasty.

J Orthop. 2015 Nov 28;12(Suppl 2):S145-51. doi: 10.1016/j.jor.2015.10.023. eCollection 2015 Dec.